The Effects of Intra-Amygdala Injection of Nicotine and Harmaline on Anxiey-Related Behavior in Adult Male Rat

Subject Areas : Journal of Chemical Health Risks

Gh. Vaezi ¹ , F. Faizy ² , R. Poozesh ³

1 - Department of Biology, Faculty of Sciences, Damghan Branch, Islamic Azad University, Damghan, Iran
2 - Department of Biology, Faculty of Sciences, Damghan Branch, Islamic Azad University, Damghan, Iran
3 - Department of Biology, Faculty of Sciences, Damghan Branch, Islamic Azad University, Damghan, Iran

Received: 2012-07-31 Accepted : 2018-10-29 Published : 2012-06-01

Keywords: Harmaline, nicotine, Amygdale, Like- anxiety behavior,

Abstract :

B-carboline alkaloids such as harmaline and nicotine are naturally present in the human food chain. Plants which contain B-caroline have anxiety and hallucinogenic effects. In this study the change in like – anxiety behaviors was investigated after intra- amygdala injections of nicotine and harmaline and intra action of them in male rat. Different doses of Harmaline, Nicotine and its compounds were applied for 30 minutes, before test of anxiety injection to (CeA) amygdale. Then like anxiety behavior include open arm time and Locomotor activity, spent open arm time, entriar open arm in maze were examined for 5 minute . Bilateral injection of Harmaline and Nicotine was decreased in to (CeA) amygdale one-by- one open arm times in control group. Injections of effective does of Nicotine could increase anxiety effects of Harmaline. Furthermore, Injection of ineffective doses of drugs has increased anxiety. The results show that Harmaline and Nicotine have anxiety effects. Also muscarinic and Nicotine receptor have important role in Like- anxiety behaviors. Acetylcholine in CeA amygdale thorough Nicotine receptors caused anxiety behaviors. Joined injection increased them effective.

References:

1. Akiyama K, Sutoo D. The relationship
2. betweenstress and epilepsy. Eur J Pharmacol
3. ; 183:227
4. Arib O, Rat P, Molimard R, Chait A, Faure P, de
5. Beaurepaire R. Electrophysiological
6. characterization of harmane-induced activation
7. of mesolimbic dopamine neurons. Eur J
8. Pharmacol 2010; 629(1-3): 47-52-
9. Bueno CH, Zangrossi H, Jr., Viana MB. The
10. inactivation of the basolateral nucleus of the rat
11. amygdala has an anxiolytic effect in the
12. elevated T-mazeand light/dark transition tests.
13. Braz J Med Biol Res 2005; 38: 1697-1701.
14. Cortese BM, Phan KL. The role of glutamate
15. inanxiety and related disorders. CNS Spectr
16. ; 10(10):820-30.
17. Davis M, Shi C. The extended amygdala: are
18. thecentral nucleus of the amygdala and the
19. bednucleus of the stria terminalis differentially
20. involved in fear versus anxiety? Ann N Y Acad
21. Sci 1999; 877: 281-91
22. File SE, Kenny PJ, Cheeta S. The role of the
23. dorsal hippocampal serotonergic and
24. cholinergic systems in the modulation of
25. anxiety. Pharmacology, biochemistry, and
26. behavior 2000; 66: 65-72
27. Freedland CS, Mansbach RS. Behavioral profile
28. of constituents in ayahuasca, an Amazonian
29. psychoactive plant mixture. Drug Alcohol
30. Depend 1999; 54:183-94
31. Fuentes JA,Longo VG.Aninvestigation on the
32. central effects of harmine,harmaline and related
33. beta-Carbolines.Neuropharmacology.1971.10(
34. :15-23.
35. Glennon RA, Dukat M, Grella B, Hong S,
36. Costantino L Teitler M, et al. Binding of betacarbolines
37. and related agents at serotonin (5-HT
38. (2) and 5-HT(1A)), dopamine (D(2)) and
39. benzodiazepine
40. receptors. Drug Alcohol Depend 2000; 60:
41. -32.
42. Gonzalez LE, Andrews N, File SE. 5-HT1A
43. and benzodiazepine receptors in the basolateral
44. amygdala modulate anxiety in the social
45. interaction test, but not in the elevated plusmaze.
46. Brain Res1996; 732: 145-153.
47. Herraiz T, Chaparro C. Human monoamine
48. oxidase is inhibited by tobacco smoke: betacarboline
49. alkaloids act as potent and reversible
50. inhibitors. Biochem Biophys Res Commun
51. 14; 326:378-86.
52. Hillberp C,Hapillon P, Effect of harmaline on
53. anxiety related behavior in mice.Physiol Behav
54. (2005) :164-167
55. Janhunen S, Ahtee L. Differential nicotinic
56. regulation of the nigrostriatal and mesolimbic
57. dopaminergic pathways: implications for drug
58. development. Neurosci Biobehav Rev 2007; 31:
59. -314.
60. Le Doux J. The emotional brain, fear, and the
61. amygdala. Cell Mol Neurobiol 2003; 23:727-
63. Liebsch G, Landgraf R, Gerstberger R, et al.
64. Chronic infusion of a CRH receptor
65. antisenseoligodeoxynucleotide into the central
66. nucleus of the amygdala reduced anxietyrelated
67. behavior insocially defeated rats.
68. Regulatory peptides, 1995; 59: 229-239.
69. Masse F, Hascoet M, Dailly E, Bourin M.
70. Effectof noradrenergic system on the
71. anxiolytic-like effectof DOI (5-HT2A/2C
72. agonists) in the four-plate
73. test.Psychopharmacology (Berl) 2006;
74. (4):471-81.
75. Pandaranandaka J, Poonyachoti S,
76. Kalandakanond-Thongsong S. Anxiolytic
77. property of estrogen related to the changes of
78. the monoamine levels in various brain regions
79. of ovariectomizedrats. Physiol Behav 2006;
80. (4):828-35.
81. Pellow S. File SE. Anxiolytic and
82. AnxiogenicDrug Effects on Exploratory
83. Activity in an Elevated Plus-Maze: a Novel
84. Test of Anxiety in the Rat.Pharmacol. Biochem
85. Behav 986;24:525-529.
86. Pfau W, Skog K. Exposure to beta-carbolines
87. norharman and harman. J Chromatogr B
88. AnalytTechnol Biomed Life Sci 2004; 802:115-
90. Picentini MP,Piatti E,franternale D,Ricci
91. D,Assorsi A.Phospholipase C-dependent
92. phosphor-inositide break down induced by EIFEMP
93. in peganum harmala call.Biochem
94. ;86( 5):343-9
95. Poorthuis RB, Goriounova NA, Couey JJ,
96. Mansvelder HD. Nicotinic actions on
97. neuronalnetworks for cognition: general
98. principles and long-term consequences.
99. Biochem Pharmacol 2009;78: 668-76.
100. Rezayat M, Roohbakhsh A, Zarrindast MR,
101. Massoudi R,Djahanguiri B. Cholecystokinin
102. and GABA interaction in the dorsal
103. hippocampus of rats in the elevated plus-maze
104. test of anxiety.
105. Physiology and behavior 2005; 84: 775-782.
106. Sharaf EL, Ansari MA, Martin four flavonoide
107. glycosidesfrom peganum harmala
108. Phytochemistry 44(1997) 533-536.
109. Spijkerman R, van den Eijnden R, van de
110. Mheen D, Bongers I, Fekkes D. The impact of
111. smoking and drinking on plasma levels of
112. norharman. Eur Neuropsychopharmacol 2002;
113. (1): 61-71
114. Squires PE, Hills CE, Rogers GJ, Garland P,
115. Farley SR, Morgan NG.The putative
116. imidazoline receptor agonist, harmane,
117. promotes intracellular calcium mobilisation in
118. pancreatic beta-cells. Eur
119. J Pharmacol 2004; 501: 31-9.
120. Walker DL, Toufexis DJ, Davis M. Rote ofthe
121. Bed Nucleus of the Stria Terminalis Versus the
122. Amygdala in Fear, Stress and Anxiety. Eur
123. JPharmacol 2003; 463:199-216.
124. Zarrindast MR, Homayoun H, Babaie A,
125. Etminani A, Gharib B. Involvement of
126. adrenergic and cholinergic systems in nicotineinduced
127. anxiogenesis in mice. Eur J Pharmacol
128. ; 407: 145-15
129. Zarrindast M, Solati J, Oryan S, Parivar K.
130. Effect of Intra-Amygdala Injection of Nicotine
131. and GABA Receptor Agents on Anxiety-Like
132. Behavior in Rats. Pharmacology 2008; 82: 276-
134. Zarrindast MR, Torabi M, Rostami P, Fazli-
135. Tabaei S. The effects of histaminergic agents in
136. the dorsal hippocampus of rats in the elevated
137. plus-maze test of anxiety. Pharmacology,
138. biochemistry, and behavior 2006; 85: 500-506.
139. Pidoplichko VI, Noguchi J, Areola OO, Liang
140. Y, Peterson J, Zhang T, et al. Nicotine
141. cholinergic Synaptic mechanisms in the ventral
142. tegmental area contribute to nicotine
143. addiction.Learn Mem,2004;11( 1):60-9